Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 347,559 | 286,497 | 193,618 | 235,184 | 298,257 |
| Marketable Securities | 1,628,269 | 1,629,213 | 1,527,619 | 1,620,101 | 1,605,569 |
| Receivables | N/A | N/A | N/A | N/A | 25,000 |
| TOTAL | $1,985,671 | $1,929,092 | $1,733,666 | $1,867,611 | $1,937,132 |
| Non-Current Assets | |||||
| PPE Net | 115,851 | 120,831 | 124,926 | 129,426 | 134,093 |
| Investments And Advances | 0 | 28,412 | 0 | 0 | 0 |
| Other Non-Current Assets | 163,721 | 166,973 | 171,119 | 169,065 | 170,809 |
| TOTAL | $279,572 | $316,216 | $296,045 | $298,491 | $304,902 |
| Total Assets | $2,265,243 | $2,245,308 | $2,029,711 | $2,166,102 | $2,242,034 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 11,138 | 11,798 | 9,753 | 13,064 | 14,709 |
| Accrued Expenses | 90,520 | 87,608 | 74,453 | 85,856 | 41,523 |
| Other current liabilities | 13,113 | N/A | N/A | N/A | 10,417 |
| TOTAL | $149,120 | $118,957 | $104,362 | $119,447 | $87,782 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 15,771 | 1,295 | 2,129 | 3,021 | 3,845 |
| Other Non-Current Liabilities | 194,310 | 198,046 | 201,901 | 205,172 | 209,849 |
| TOTAL | $194,310 | $210,369 | $214,224 | $217,495 | $222,172 |
| Total Liabilities | $343,430 | $329,326 | $318,586 | $336,942 | $309,954 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 95,985 | 95,300 | 90,950 | 86,364 | 85,774 |
| Common Shares | 3,087 | 3,013 | 2,794 | 2,721 | 2,698 |
| Retained earnings | -1,947,551 | -1,816,938 | -1,710,497 | -1,501,948 | -1,365,952 |
| Other shareholders' equity | 4,761 | 4,926 | 3,979 | 4,073 | 1,778 |
| TOTAL | $1,921,813 | $1,915,982 | $1,711,125 | $1,829,160 | $1,932,080 |
| Total Liabilities And Equity | $2,265,243 | $2,245,308 | $2,029,711 | $2,166,102 | $2,242,034 |